跳至主要内容
临床试验/JPRN-jRCT1071210024
JPRN-jRCT1071210024已完成4 期

Vaccine effectiveness, immunogenicity and safety of COVID-19 vaccine among lung cancer patients undergoing chemotherapy: prospective cohort study

akashima Kei0 个研究点目标入组 93 人开始时间: 2021年5月18日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
93

研究概览

简要总结

BNT162b2 vaccination in lung cancer patients undergoing anticancer treatment significantly increased antibody titers and showed acceptable safety. Immunogenicity in these patients could be inadequate compared with that in non-cancer patients.

研究设计

研究类型
Observational

入排标准

年龄范围
>= 50age old 至 ot applicable(—)
性别
All

入选标准

  • 1) Any of the following a or b
  • a Patients with lung cancer on chemotherapy over 50 years
  • b Patients with underlying disease (except for cancer) over 50 years old
  • 2) Those who are visiting a medical institution conducting research (Kameda Medical Center, Chikamori hospital)
  • 3) Subjects who voluntarily recieve the COVID-19 vaccine
  • 4) Written informed consent

排除标准

  • 1) Those who have the contraindications for vaccination
  • 2) Those who have been vaccinated with the new coronavirus vaccine in the past
  • (Including participation in clinical trials or clinical trials / research)
  • 3) Those who are receiving systemic steroids / immunosuppressants (excluding administration of anticancer drugs as antiemetics)
  • 4) Persons with autoimmune disease under treatment
  • 5) Those who have experienced an acute illness that requires antibiotics or steroids within the past one month
  • 6) Those who have a fever at the time of vaccination, those who present with acute serious illness
  • 7) Persons who are judged by the principal investigator or the investigator to be inappropriate as research subjects

研究者

发起方
akashima Kei

相似试验